Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM G WIERDA and KUMUDHA BALAKRISHNAN.
Connection Strength
1.206
-
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
Score: 0.147
-
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
Score: 0.139
-
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
Score: 0.125
-
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
Score: 0.107
-
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
Score: 0.091
-
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.
Score: 0.081
-
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 01; 112(5):1971-80.
Score: 0.080
-
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
Score: 0.066
-
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
Score: 0.063
-
The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
Score: 0.038
-
B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703.
Score: 0.038
-
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
Score: 0.036
-
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
Score: 0.036
-
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
Score: 0.032
-
Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
Score: 0.031
-
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):899-910.
Score: 0.029
-
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
Score: 0.025
-
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
Score: 0.022
-
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
Score: 0.021